Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Abstract from Movement Disorders Conference

June 22, 2016 Kerry Rowe

Abstract from Movement Disorders Conference 2016

Post navigation

Prana’s Huntington Disease trial analysis to feature at global movement disorder conference

Prana Alzheimer’s disease data features at world leading conference

Related Posts

Prana’s Parkinson’s drug meets Michael J. Fox Foundation development milestone – PBT434 advances through IND enabling studies

July 17, 2013

Chairman’s Address to Shareholders 2019 Annual General Meeting

November 26, 2019November 26, 2019

Prana Receives Approval For 12-Month Open Label Extension Study In Alzheimer’s Disease

July 17, 2013May 5, 2019

Recent Posts

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate
Chairman’s Address to Shareholders 2019 Annual General Meeting

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065